The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.

Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB

Diabetologia1 May 1998Cited by 78 (Europe PMC)

PMID9628276DOI10.1007/s001250050949PepBankPUB-09628276

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, pramlintide delayed first-meal solid gastric emptying versus placebo.
In plain wordsIn men with insulin-dependent diabetes, pramlintide slowed stomach emptying after the first meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseFirst-meal solid gastric emptying
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide delayed emptying of the solid component of the first meal (p < 0.004) with no significant difference between the drug doses.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827601
02HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, pramlintide delayed first-meal solid gastric emptying versus placebo.
In plain wordsIn men with insulin-dependent diabetes, pramlintide slowed stomach emptying after the first meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseFirst-meal solid gastric emptying
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
60 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide delayed emptying of the solid component of the first meal (p < 0.004) with no significant difference between the drug doses.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827602
03HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, pramlintide delayed first-meal solid gastric emptying versus placebo.
In plain wordsIn men with insulin-dependent diabetes, pramlintide slowed stomach emptying after the first meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseFirst-meal solid gastric emptying
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
90 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide delayed emptying of the solid component of the first meal (p < 0.004) with no significant difference between the drug doses.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827603
04HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, first-meal solid gastric emptying did not differ significantly between pramlintide doses.
In plain wordsIn men with insulin-dependent diabetes, stomach emptying after the first meal did not differ significantly between pramlintide doses.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeFirst-meal gastric emptying dose comparison
Study
n = 11
Comparator
Other pramlintide doses
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30, 60 or 90 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide delayed emptying of the solid component of the first meal (p < 0.004) with no significant difference between the drug doses.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827604
05HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, gastric emptying after the second meal did not differ between pramlintide and placebo.
In plain wordsIn men with insulin-dependent diabetes, stomach emptying after the second meal was similar with pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeSecond-meal gastric emptying
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30, 60 or 90 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
There were no differences between placebo and pramlintide after the second meal.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827605
06HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, pramlintide prolonged time to peak plasma 3-OMG after the first meal versus placebo.
In plain wordsIn men with insulin-dependent diabetes, pramlintide delayed peak 3-OMG after the first meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseFirst-meal time to peak 3-OMG
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide resulted in a prolongation in the time to peak plasma 3-OMG level (p < 0.0001) after the first meal but there was no difference after the second meal.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827606
07HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, pramlintide prolonged time to peak plasma 3-OMG after the first meal versus placebo.
In plain wordsIn men with insulin-dependent diabetes, pramlintide delayed peak 3-OMG after the first meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseFirst-meal time to peak 3-OMG
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
60 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide resulted in a prolongation in the time to peak plasma 3-OMG level (p < 0.0001) after the first meal but there was no difference after the second meal.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827607
08HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, pramlintide prolonged time to peak plasma 3-OMG after the first meal versus placebo.
In plain wordsIn men with insulin-dependent diabetes, pramlintide delayed peak 3-OMG after the first meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseFirst-meal time to peak 3-OMG
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
90 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide resulted in a prolongation in the time to peak plasma 3-OMG level (p < 0.0001) after the first meal but there was no difference after the second meal.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827608
09HumanRandomized controlled trialEfficacy outcome
In men with insulin-dependent diabetes, time to peak plasma 3-OMG after the second meal did not differ versus placebo.
In plain wordsIn men with insulin-dependent diabetes, peak 3-OMG timing after the second meal was similar with pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeSecond-meal time to peak 3-OMG
Study
n = 11
Comparator
Placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
30, 60 or 90 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
All three doses of pramlintide resulted in a prolongation in the time to peak plasma 3-OMG level (p < 0.0001) after the first meal but there was no difference after the second meal.
2 context sentences(design, population, supporting numbers)
Summary · context
Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design.
Summary · context
At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously.
Report a problemFND-0962827609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.